scholarly journals Efficacy of Korean Red Ginseng by Single Nucleotide Polymorphism in Obese Women: Randomized, Double-blind, Placebo-controlled Trial

2012 ◽  
Vol 36 (2) ◽  
pp. 176-189 ◽  
Author(s):  
Dong-Hyun Kwon ◽  
Shambhunath Bose ◽  
Mi-Young Song ◽  
Myeong-Jong Lee ◽  
Chi-Yeon Lim ◽  
...  
Keyword(s):  
Single Nucleotide Polymorphism ◽  
Controlled Trial ◽  
Obese Women ◽  
Red Ginseng ◽  
Nucleotide Polymorphism ◽  
Korean Red Ginseng ◽  
Double Blind ◽  
Single Nucleotide ◽  
Double Blind Placebo

scholarly journals Immuno-enhancement effects of Korean Red Ginseng in healthy adults: a randomized, double-blind, placebo-controlled trial

2021 ◽  
Vol 45 (1) ◽  
pp. 191-198
Author(s):  
Sun Hee Hyun ◽  
Ha-Young Ahn ◽  
Hyeong-Jun Kim ◽  
Sung Won Kim ◽  
Seung-Ho So ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Healthy Adults ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effects of Korean Red Ginseng on Dry Mouth: A Randomized, Double-Blind, Placebo-Controlled Trial

2010 ◽  
Vol 34 (3) ◽  
pp. 183-191 ◽  
Author(s):  
Jae-Woo Park ◽  
Beom-Joon Lee ◽  
Young-Min Bu ◽  
In-Kwon Yeo ◽  
Jin-Sung Kim ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Dry Mouth ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Supplementation with Korean Red Ginseng Improves Current Perception Threshold in Korean Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Kahui Park ◽  
YuSik Kim ◽  
Junghye Kim ◽  
Shinae Kang ◽  
Jong Suk Park ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Controlled Trial ◽  
Diabetes Duration ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Double Blind ◽  
Perception Threshold ◽  
Double Blind Placebo ◽  
Current Perception Threshold

Background. Many Type 2 diabetes (T2DM) patients in Korea take Korean Red Ginseng (KRG) for various reasons. In this study, we investigated the effects of KRG administration on diabetic peripheral neuropathy in T2DM patients. Methods. This study was a randomized, double-blind, placebo-controlled trial. Participants were randomly allocated to either the placebo or KRG group and took corresponding tablets for 24 weeks. The primary outcomes were changes in current perception threshold (CPT) at week 24. Secondary outcomes were altered fasting plasma glucose, HbA1c, and various metabolic and inflammatory markers at week 24. Results. Sixty-one patients completed the study. The CPT of the lower extremities at various frequencies exhibited significant improvements at week 24 in the KRG group. Other metabolic parameters were not altered after 24 weeks in both groups. In the subgroup analysis, CPT levels were improved in those with a longer diabetes duration or who already had neuropathy at the beginning of the study, and insulin resistance was improved in patients with a shorter diabetes duration. Conclusion. Twenty-four week administration of KRG in T2DM patients resulted in a significant improvement in neuropathy, especially in those with a longer diabetes duration. A further, larger population study with a longer follow-up period is warranted to verify the effects of KRG on diabetic neuropathy.

Sign in / Sign up

Export Citation Format

Share Document